Houston, United States
Research view
Kidney cancer: who works on it
Groups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
Find fellow researchers
One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.
- All targets
- PD-1 21
- PD-L1 11
- VEGF 10
- mTOR 1
- AKT 0
- VHL 6
- PI3K 0
- PSMA 10
- STAT3 0
- BAP1 1
- TP53 0
- JAK 0
- CTLA-4 4
- STING 1
- ALK 1
- EGFR 3
- TFEB 0
- ERK 0
- MYC 0
- HIF-1 0
- YAP 0
- AMPK 0
- CTNNB1 0
- MET 2
- B7-H3 2
- MAPK 0
- PPAR 0
- FGFR 1
- GLP-1 0
- GPC3 3
- HER2 2
- IL-6 0
- MMP-9 0
- PARP 1
- AXL 1
- BCL-2 0
- EZH2 0
- IDH 1
- NTRK 0
- PTEN 0
- BRAF 1
- CD19 1
- CDKN2A 0
- JNK 0
- KRAS 1
- LAG-3 0
- METTL3 1
- NLRP3 0
- NRF2 0
- PKM2 0
- ROS1 0
- TNF 0
- APOE 0
- BRCA1 0
- BRCA2 0
- BRD4 0
- CD20 0
- CDK4/6 0
- DPP-4 0
- FOXP3 0
EU-13 is a filter, not a ranking: it only narrows the list.
Boston, United States
Duarte, United States
San Diego, United States
Cleveland, United States
Rochester, United States
Atlanta, United States
Boston, United States
Ann Arbor, United States
Beijing, China
Rome, Italy
Chengdu, China
San Francisco, United States
Salt Lake City, United States
Seattle, United States
Barcelona, Spain
Tampa, United States
London, United Kingdom
Milan, Italy
Beijing, China
Seoul, South Korea
Nanjing, China
Guangzhou, China
Amsterdam, Netherlands
24 of 63+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Who stopped a trial, and why
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
High Dose IL-2 in Combination With Anti-PD-1
“Lack of funding”Registry text, quoted unchanged. Source
Terminated
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
“Lack of activity in the drugs”Registry text, quoted unchanged. Source
Terminated
Study of PF-07265807 in Participants With Metastatic Solid Tumors.
“Pfizer has made an internal business decision to not continue further development of PF-07265807. This decision was not due to major safety concerns or requests from any regulatory authorities.”Registry text, quoted unchanged. Source
Terminated
ITIL-306 in Advanced Solid Tumors
“The study was terminated early due to discontinuation of development of the investigational program”Registry text, quoted unchanged. Source
Terminated
A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer
“The trial was terminated for strategic reasons. The decision was not based on any safety and/or efficacy concerns”Registry text, quoted unchanged. Source
Terminated
“Study terminated as part of strategic considerations and not based on safety concerns.”Registry text, quoted unchanged. Source
Terminated
“Business Decision”Registry text, quoted unchanged. Source
Terminated
“This study was terminated as a result of Sponsor portfolio reprioritization.”Registry text, quoted unchanged. Source
Terminated
“The trial was terminated for strategic business reasons; the decision was not based on any safety and/or efficacy concerns.”Registry text, quoted unchanged. Source
Trials that share participant data
Trials whose registry record says individual participant data (IPD) will be shared.
Search by method
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
- Single-Cell Analysis 37
- Organoids 4
- Mendelian Randomization Analysis 22
- CRISPR-Cas Systems 8
- Gene Expression Profiling 97
- Sequence Analysis, RNA 2
- Whole Genome Sequencing 6
- Exome Sequencing 10
- Proteomics 25
- Metabolomics 12
- Mass Spectrometry 3
- Flow Cytometry 11
- Immunohistochemistry 95
- Liquid Biopsy 6
- Circulating Tumor DNA 8
- Xenograft Model Antitumor Assays 76
- Positron-Emission Tomography 13
- Magnetic Resonance Imaging 60
- Machine Learning 70
- Deep Learning 36
- Cohort Studies 67
- Genome-Wide Association Study 19
Paste an abstract
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed. Machine-matched links are labelled.